A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis

Trial Profile

A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms faSScinate
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 May 2016 Results published in The Lancet.
    • 14 Sep 2015 New source identified and integrated (European Clinical Trials Database; EudraCT2011-001460-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top